Articles tagged with Oncology
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
A cohort study found combined GLP-1RA and progestin therapy reduces endometrial cancer risk in women with benign uterine pathology or endometrial hyperplasia. The study suggests potential benefits of this treatment approach for nonmalignant uterine diseases.
Researchers found that an experimental compound SB-216 reduced the growth of pancreatic ductal adenocarcinoma cells by inhibiting oncogenic microtubules and mitochondrial function. This approach may reduce cancer cell adaptation and survival.
Researchers found that PSMA PET/CT scans can help guide treatment planning and improve long-term outcomes for patients with recurring prostate cancer. The study suggests that incorporating these scans into routine care may lead to better results and reduced side effects.
A study found that historical redlining has a lasting impact on breast cancer survival, with disparities narrowing from 1995-2014 but increasing in 2015-2019. Redlining-associated mortality disparities were mostly seen in patients with less advanced tumors.
Ovarian cancer cells recruit protective mesothelial cells in abdominal fluid to form hybrid cell clusters that resist chemotherapy. These clusters use spike-like structures called invadopodia to invade surrounding tissue. The discovery opens new treatment possibilities and could help doctors monitor disease progression.
A recent cohort study found that individuals diagnosed with cancer in 2020 and 2021 experienced worse short-term survival rates compared to those diagnosed between 2015 and 2019. The study suggests substantial harms associated with cancer care disruptions during the COVID-19 pandemic.
A study of US veterans has identified a possible link between exposure to Agent Orange and acral melanoma, a rare form of skin cancer. The researchers found that veterans exposed to the herbicide had a 30% higher odds of developing this type of melanoma.
The National Comprehensive Cancer Network (NCCN) has committed to updating its robust information resources for cancer patients and caregivers annually, available in both English and Spanish. The updated resources will provide factual, trustworthy information to guide patients and caregivers towards their best possible outcome.
A new study published in Gastroenterology has investigated the link between ulcerative proctitis and rectal cancer, revealing no increased risk in patients with isolated proctitis. The study followed nearly 16,000 people with ulcerative proctitis for over ten years, finding a low incidence of rectal cancer and precancerous lesions.
A study published in PNAS successfully eliminated pancreatic tumours in mice completely and durably, with no significant side effects. The treatment, combining three molecular targets, induced robust regression of experimental PDACs without causing tumor resistance.
A new questionnaire-based scale assesses nursing practices supporting fertility preservation decisions in women with cancer. The study highlights three essential dimensions of nursing practice: professional decision-support, communication facilitation, and system-based collaboration.
A recent systematic review has compiled and catalogued publicly available omics data on pituitary tumours, highlighting the need for standardisation and clinical annotation. The resulting catalogue facilitates the reuse of data for future research projects and precision medicine initiatives.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Iakovos Toumazis leads IDSO's focus area on decision analytics for health to optimize patient outcomes and resource allocation. His research informs data-driven approaches to cancer prevention and policy decisions.
A recent study found that low-dose aspirin use was not associated with incident cancer incidence in older adults, contrary to previous findings. However, the study revealed a significant elevation in cancer mortality risk during the randomized clinical trial period, which did not persist after the trial ended.
A new AI tool has been developed to predict the chances of death, major bleeding, or another cardiac event in cancer patients who have had a heart attack. The ONCO-ACS score combines cancer-related factors with standard clinical data to provide individualized treatment recommendations.
Early recognition and surgical management are crucial in treating necrotizing fasciitis of the head and neck, a rare but life-threatening soft tissue infection. The authors emphasize the urgent need for coordinated care, including immediate surgery, broad-spectrum antibiotics, and airway protection to reduce mortality rates.
A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
Researchers successfully diagnosed and treated ten PCNSL patients using liquid biopsy, detecting hotspot MYD88 L265P mutations in circulating tumor DNA. This method offers a reliable alternative to surgical biopsies for patients with difficult-to-access lesions or frailty, enabling timely treatment initiation.
Researchers developed bioengineered lymphatic tissue (CeLyT) that restored functional lymph nodes in mice with secondary lymphedema. CeLyTs improved lymphedema symptoms by restoring lymphatic flow, filtration capacity, and immune cell populations.
Scientists at UNIGE created an AI tool called MangroveGS that can accurately predict the risk of cancer metastasis and recurrence. The algorithm uses gene expression signatures from colon cancer cells to identify key factors influencing metastatic potential, paving the way for more precise care and discovery of new therapeutic targets.
Cancer mortality rates have decreased for breast cancer and leukemia, despite increasing incidence, while colorectal cancer has become the leading cause of death among US young adults. Colorectal cancer surpasses lung, breast, and prostate cancers as the leading cancer-related death in people under 50 years old.
Sujuan Ba, CEO of the National Foundation for Cancer Research, has been recognized as one of OncoDaily's 100 Most Influential CEOs in Oncology in 2025. Under her leadership, NFCR has strengthened its role as a strategic accelerator of cancer research, supporting innovative science and fostering cross-sector collaboration.
A rare diagnosis of a giant solitary neurofibroma in a 13-year-old boy was successfully treated with microsurgery. The tumor's location deep within the thigh along the sciatic nerve made it challenging to diagnose and treat, but careful surgical technique and postoperative care ensured optimal outcomes.
Dr. Brian Leyland-Jones was a renowned breast cancer oncologist and translational research leader who played a pivotal role in advancing cancer therapies. He made himself available to patients in need, offering his expertise pro bono and guiding them through diagnoses and treatment options.
Population risk-based screening using 5-year invasive breast cancer risk is associated with similar or greater benefits than age-based screening, as well as reduced false-positive recalls. As personalized medicine advances, risk-based screening is poised to become a cornerstone of breast cancer prevention.
A new blood test has identified a protein signature linked to cancer in patients with non-specific symptoms. The test distinguishes cancer from other conditions with high precision and can help prioritize patients for further diagnostics.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
Ochsner MD Anderson is offering histotripsy, a revolutionary non-invasive treatment for liver tumors, approved by the FDA in 2023. The procedure uses ultrasound energy to destroy liver tumors in a single outpatient procedure.
A machine-learning-based approach has been developed to map real-time tumor metabolism in brain cancer patients, helping doctors discover effective treatment strategies. The digital twin uses patient data to calculate metabolic flux, predicting which treatments are likely to work for individual cases of glioma.
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
The collaboration aims to integrate AI-powered analytics with clinical expertise to accelerate data-driven cancer care. MD Anderson researchers will leverage SOPHIAs AI technologies to develop bioinformatics pipelines for rapid RNA-sequencing data interpretation.
Researchers found that pitavastatin directly inhibits the anti-apoptotic protein Mcl-1, a key driver of survival and resistance in TNBC cells. The study showed pitavastatin effectively eliminates cancer stem-like cell populations and reduces tumor growth, angiogenesis, and lung metastasis.
Researchers identified specific microbial patterns associated with tumor location, genetic features, and patient outcomes. A new Microbial Risk Score (MRS) offers a practical way to translate complex microbiome data into prognostic insight.
A recent study published in Gut journal revealed that Streptococcus anginosus produces methionine metabolites, which significantly contribute to the development of gastric cancer. The research opens new paths for microbiota-targeted prevention strategies.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Insilico Medicine collaborates with Servier to develop novel therapeutics in oncology through AI-driven platform Pharma.AI. The partnership is focused on identifying promising targets and generating molecular structures with desired properties.
Researchers discovered a novel mechanism behind small cell lung cancer's aggressiveness, involving the lack of caspase-8, leading to necroptosis and inflammation that fosters tumor progression. This pre-tumoral inflammation suppresses anti-cancer immune responses, promoting metastasis and relapse.
Early gastric cancer cells become self-sufficient by producing WNT7B, creating a self-sustaining loop and activating WNT signaling internally. This mechanism is triggered by MAPK signaling activation and has been validated in genetically engineered mouse models and human patient-derived organoids.
A recent review suggests that Clostridioides difficile infection may promote the development of gastrointestinal tumors, including colorectal cancer. The bacterium's toxins can cause damage to the epithelial cytoskeleton and induce inflammation, leading to chronic colitis and increased risk of CRC.
A new study by researchers from the Germans Trias i Pujol Research Institute provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer. The review highlights molecular, cellular, and tumour microenvironment factors that explain the therapeutic dichotomy between the two tumour types.
A new study found that quadrivalent human papillomavirus (HPV) vaccination is associated with a reduced risk of high-grade vulvovaginal lesions. Expanding HPV vaccination, especially at younger ages, may help prevent these lesions.
A new study published in JAMA Oncology found that the HPV vaccine can protect against severe precancerous lesions of the vulva and vagina. Vaccination before the age of 17 offers the strongest protection, with a 55% lower risk compared to unvaccinated women.
Researchers have developed an ultrasensitive liquid biopsy platform to predict and monitor immunotherapy response in advanced cancer patients. The study shows that lower levels of circulating tumor DNA (ctDNA) at baseline are associated with better progression-free survival and overall survival.
Researchers used machine learning to combine clinical data with biological markers, achieving 89.58% accuracy in predicting patient survival. The study identified key markers such as E2F8, WDR77, and hsa-miR-495-3p, which were associated with tumor growth and cancer development.
Studies show that patients with advanced ovarian and metastatic breast cancer dedicate approximately 7 hours per week to cancer-related tasks. Most participants report performing these tasks daily, impacting their time burden. The use of a mobile app facilitated the collection of detailed time-use data.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Maher El-Kady's work on sustainable energy storage technologies aims to create a cleaner, more accessible future. Dr. Dennis Slamon's breakthroughs in breast cancer treatment have benefited millions worldwide, highlighting the impact of UCLA researchers on global health and innovation.
A phase two trial found that adding dinutuximab beta to chemotherapy improves the best objective response rate and overall survival time for children with relapsed or refractory neuroblastoma. The treatment resulted in a significant increase in patients' tumors shrinking after six cycles of treatment.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
Veterans and first responders face elevated risk of cancer due to occupational exposures, such as firefighting. Experts call for better access to high-quality cancer prevention, screening, and treatment, including presumptive laws and expanded support services.
The MUTE-Seq method detects rare cancer mutations at exceptionally low frequencies, enriching circulating tumor DNA and improving detection accuracy. It increases variant allele frequencies by tens of times, enabling detection of mutations present at 0.005% or lower.
NEJM Clinician curates highly relevant clinical insights from over 150 peer-reviewed journals to give physicians clear guidance without the noise. The weekly publication delivers summaries and commentary in a concise, 30-minute read, helping healthcare providers stay informed and confident in their decisions.
A new study by researchers at Karolinska Institutet found that lower doses of approved immunotherapy drugs can give better results against tumours, while reducing side effects. The regimen with the lower dose of ipilimumab was more effective, with a higher proportion of patients responding to treatment and longer overall survival.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
Researchers from Mass General Brigham Cancer Institute present promising new treatment options for acute myeloid leukemia, autoimmune bleeding disorders, and multiple myeloma. The studies show improved event-free survival, higher overall response rates, and better quality of life for patients treated with novel therapies.
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
Insilico Medicine has nominated ISM3830, a highly selective CBLB inhibitor, as a preclinical candidate for advanced tumor immunotherapy. ISM3830 showed robust anti-tumor activity in multiple murine models and induction of long-term tumor immunity.